抗心律失常药
抗心律失常药物主要用于防治过速性心律失常。近年来，随着电生理学研究的深入，对抗心律失常药物的作用机制有了更深刻的认识；同时，体内含量微量测定法的应用使得我们能够依据药代动力学原则制定有效的用药方案。通过连续监测心电图并借助计算机技术评估血药浓度与临床疗效的关系，这些进展极大地促进了新药的研发及心律失常的治疗。
根据抗心律失常药物的电生理学特点，人们提出了多种分类方法。目前通常将其分为四类：膜稳定剂、动作电位时程和不应期延长剂、β-受体阻断药以及钙拮抗剂。也有学者将前两类称为非特异性抗心律失常药，而后两类则归为特异性抗心律失常药。
| 中文名称 | 英文名称 | CAS号 | 化学式 |
|---|---|---|---|
| 氟卡尼 | flecainide | 54143-55-4 | C17H20F6N2O3 |
| 比索洛尔 | bisoprolol | 66722-44-9 | C18H31NO4 |
| 普鲁卡因胺 | 4-amino-N-(2-diethylaminoethyl)benzamide | 51-06-9 | C13H21N3O |
| 普萘洛尔 | propranolol | 525-66-6 | C16H21NO2 |
| 普拉洛尔 | practolol | 6673-35-4 | C14H22N2O3 |
| 左布诺洛尔 | levobunolol | 47141-42-4 | C17H25NO3 |
| 尼非卡兰 | Nifekalant | 130636-43-0 | C19H27N5O5 |
| 富马酸比索洛尔 | bisoprolol Fumarate | 104344-23-2 | C4H4O4*C18H31NO4 |
| 安他唑啉 | antazoline | 91-75-8 | C17H19N3 |
| 妥卡尼 | tocainide | 41708-72-9 | C11H16N2O |
| 奎尼丁硫酸盐 | quinidine sulfate | 747-45-5 | 2C20H24N2O2*H2O4S |
| 奎尼丁 | quinidine | 56-54-2 | C20H24N2O2 |
| 奎宁硫酸盐 | quinine sulphate | 549-56-4 | C20H24N2O2*H2O4S |
| 多非利特 | dofetilide | 115256-11-6 | C19H27N3O5S2 |
| 塞利洛尔 | celiprolol | 56980-93-9 | C20H33N3O4 |
| 噻吗洛尔 | timolol | 26839-75-8 | C13H24N4O3S |
| 吲哚洛尔 | 1-(1H-indol-4-yloxy)-3-(isopropylamino)-2-propanol | 13523-86-9 | C14H20N2O2 |
| 吡西卡尼 | pilsicainide | 88069-67-4 | C17H24N2O |
| 去甲基衡州乌药碱 | higenamine | 5843-65-2 | C16H17NO3 |
| 卡替洛尔 | carteolol | 51781-06-7 | C16H24N2O3 |
| 决奈达隆 | dronedarone | 141626-36-0 | C31H44N2O5S |
| 倍他索洛尔 | betaxolol | 63659-18-7 | C18H29NO3 |
| 伊布利特 | ibutilide | 122647-31-8 | C20H36N2O3S |
| N-乙酰普鲁卡因胺 | N-acetylprocainamide | 32795-44-1 | C15H23N3O2 |
| N-(4-氯苯基)-n-(1-异丙基-4-哌啶)苯乙酰胺盐酸盐 | Lorcainide hydrochloride | 58934-46-6 | C22H27ClN2O*ClH |
| 5-对甲苯基-1H-四氮唑 | 5-(p-tolyl)-1H-tetrazole | 24994-04-5 | C8H8N4 |
| 1-[2-[2-羟基-3-(丙氨基)-丙氧基]苯基]-3-苯基-1-丙酮 | propafenone | 54063-53-5 | C21H27NO3 |
| (+)-鹰爪豆碱 | sparteine | 492-08-0 | C15H26N2 |
| —— | epi-dihydroquinine | 522-66-7 | C20H26N2O2 |
| —— | (R)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid | 50-54-4 | C40H50N4O8S |
| —— | (S)-[(2R,5R)-5-ethylquinuclidin-2-yl]-(6-methoxy-4-quinolyl)methanol | 1435-55-8 | C20H26N2O2 |
| —— | (S)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid | 7054-25-3 | C26H36N2O9 |
| —— | Quinaglute (TN) | 7054-25-3 | C26H36N2O9 |
| —— | (S)-[(2R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid | 50-54-4 | C40H50N4O8S |
| —— | (+)-sparteine | 90-39-1 | C15H26N2 |
| —— | (R)-Timolol (maleate) | 26791-17-3 | C17H28N4O7S |
| —— | (2R,3R)-2,3-dihydroxybutanedioate;[2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl]-propan-2-ylazanium | 56392-17-7 | C34H56N2O12 |
| —— | Quinidine Sulfate | 50-54-4 | C40H50N4O8S |
| —— | β-isosparteine | 90-39-1 | C15H26N2 |
| —— | Spartein | 90-39-1 | C15H26N2 |
| —— | α-Isospartein | 90-39-1 | C15H26N2 |
| —— | (+)-sparteine | 90-39-1 | C15H26N2 |
| —— | Quinidine sulfate dihydrate | 6591-63-5 | C40H54N4O10S |
| —— | (-)-sparteine | 90-39-1 | C15H26N2 |
| —— | (S)-oxprenolol | 22972-96-9 | C15H23NO3 |
| —— | bis{1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol} (2E)-but-2-enedioic acid | 104344-23-2 | C40H66N2O12 |
| —— | (S)-[(4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid | 7054-25-3 | C26H36N2O9 |
| —— | (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol;sulfuric acid | 50-54-4 | C40H50N4O8S |
| —— | Bisoprolol; butenedioic acid | 104344-23-2 | C22H35NO8 |
| —— | R-Timolol 2-butenedioate | 26839-77-0 | C17H28N4O7S |
联系我们
关注我们
公众号
